 | Up a level |
2022
Rob, Lukas 
ORCID: 0000-0003-3770-651X, Cibula, David ORCID: 0000-0001-6387-9356, Knapp, Pawel, Mallmann, Peter, Klat, Jaroslav, Minar, Lubos, Bartos, Pavel, Chovanec, Josef, Valha, Petr, Pluta, Marek, Novotny, Zdenek, Spacek, Jiri, Melichar, Bohuslav, Kieszko, Dariusz, Fucikova, Jitka, Hrnciarova, Tereza, Korolkiewicz, Roman Pawel, Hraska, Marek, Bartunkova, Jirina and Spisek, Radek
(2022).
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
J. Immunother. Cancer, 10 (1).
LONDON:
BMJ PUBLISHING GROUP.
ISSN 2051-1426
2021
Cibula, David, Rob, Lukas ORCID: 0000-0003-3770-651X, Mallmann, Peter, Knapp, Pawel, Klat, Jaroslav, Chovanec, Josef, Minar, Lubos, Melichar, Bohuslav, Hein, Alexander, Kieszko, Dariusz, Pluta, Marek, Spacek, Jiri, Bartos, Pavel, Wimberger, Pauline, Madry, Radoslaw, Markowska, Janina, Streb, Joanna, Valha, Petr, Bin Hassan, Hariz Iskandar, Pecen, Ladislav, Galluzzi, Lorenzo, Fucikova, Jitka, Hrnciarova, Tereza, Hraska, Marek, Bartunkova, Jirina and Spisek, Radek
(2021).
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Gynecol. Oncol., 162 (3).
S. 652 - 661.
SAN DIEGO:
ACADEMIC PRESS INC ELSEVIER SCIENCE.
ISSN 1095-6859
Rob, Lukas ORCID: 0000-0003-3770-651X, Cibula, David, Knapp, Pawel, Mallmann, Peter, Klat, Jaroslav, Minar, Lubos, Bartos, Pavel, Chovanec, Josef, Valha, Petr, Pluta, Marek, Novotny, Zdenek, Spacek, Jiri, Melichar, Bohuslav, Kieszko, Dariusz, Fucikova, Jitka, Hrnciarova, Tereza, Korolkiewicz, Roman Pawel, Hraska, Marek, Bartunkova, Jirina and Spisek, Radek
(2021).
Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial.
J. Clin. Oncol., 39 (15).
PHILADELPHIA:
LIPPINCOTT WILLIAMS & WILKINS.
ISSN 1527-7755
2018
Cibula, David, Mallmann, Peter, Knapp, Pawel, Melichar, Bohuslav, Klat, Jaroslav ORCID: 0000-0001-9762-1345, Minar, Lubos, Novotny, Zdenek, Wimberger, Pauline, Hein, Alexander, Spisek, Radek, Bartunkova, Jirina, Pecen, Ladislav, Bin Hassan, Hariz Iskandar and Rob, Lukas
(2018).
Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial.
J. Clin. Oncol., 36 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
Rob, Lukas, Mallmann, Peter, Knapp, Pawel, Melichar, Bohuslav, Klat, Jaroslav ORCID: 0000-0001-9762-1345, Minar, Lubos, Novotny, Zdenek, Bartunkova, Jirina, Spisek, Radek, Pecen, Ladislav, Bin Hassan, Hariz Iskandar and Cibula, David
(2018).
Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial.
J. Clin. Oncol., 36 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755
2014
Rob, Lukas, Bartunkova, Jirina, Cibula, David ORCID: 0000-0001-6387-9356, Knapp, Pawel ORCID: 0000-0003-3008-616X, Namestkova, Zurana, Splsek, Radek, Waclav, Jan and Mallmann, Peter
(2014).
Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC).
J. Clin. Oncol., 32 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755